Changes in the V3 region of gp 120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Δ32 heterozygote

被引:33
|
作者
Gorry, Paul R.
Dunfee, Rebecca L.
Mefford, Megan E.
Kunstman, Kevin
Morgan, Tom
Moore, John P.
Mascola, John R.
Agopian, Kristin
Holm, Geoffrey H.
Mehle, Andrew
Taylor, Joann
Farzan, Michael
Wang, Hui
Ellery, Philip
Willey, Samantha J.
Clapham, Paul R.
Wolinsky, Steven M.
Crowe, Suzanne M.
Gabuzda, Dana
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA
[4] Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA
[5] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[6] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
[7] Macfarlane Burnet Inst Med Res & Publ Hlth, Melbourne, Vic, Australia
[8] Monash Univ, Dept Med, Clayton, Vic 3168, Australia
[9] Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Program Mol Med, Worcester, MA 01655 USA
关键词
HIV-1; CCR5; Delta; 32; ENV; V3;
D O I
10.1016/j.virol.2006.11.025
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Heterozygosity for the CCR5 Delta 32 allele is associated with delayed progression to AIDS in human immunodeficiency virus type 1 (HIV-1) infection. Here we describe an unusual HIV-1 isolate from the blood of an asymptomatic individual who was heterozygous for the CCR5 Delta 32 allele and had reduced levels of CCR5 expression. The primary virus used CCR5, CXCR4, and an unusually broad range of alternative coreceptors to enter transfected cells. However, only CXCR4 and CCR5 were Used to enter primary T cells and monocyte-derived macrophages, respectively. Full-length Env clones had an unusually long V1/V2 region and rare amino acid variants in the V3 and C4 regions. Mutagenesis studies and structural models suggested that Y308, D321, and to a lesser extent K442 and E444, contribute to the broad coreceptor usage of these Envs, whereas 1317 is likely to be a compensatory change. Furthermore, database analysis suggests that covariation can occur at positions 308/317 and 308/321 in vivo. Y308 and D321 reduced dependence on the extracellular loop 2 (ECL2) region of CCR5, while these residues along with Y330, K442, and E444 enhanced dependence on the CCR5 N-terminus compared to clade B consensus residues at these positions. These results suggest that expanded coreceptor usage of HIV-1 can occur in some individuals without rapid progression to AIDS as a consequence of changes in the V3 region that reduce dependence on the ECL2 region of CCR5 by enhancing interactions with conserved structural elements in G-protein-coupled receptors. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:163 / 178
页数:16
相关论文
共 50 条
  • [21] Model of the functioning of the V3 loop central epitope of HIV-1 gp120 in complex with antibodies
    Shchelkanov, MY
    Yaroslavtseva, NG
    Emel'yanov, AV
    Sakhuriya, IB
    Abelyan, AV
    Verevochkin, SV
    Kozlov, AP
    Karamov, EV
    MOLECULAR BIOLOGY, 1998, 32 (06) : 899 - 909
  • [22] Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing Fabs
    Stanfield, RL
    Cabezas, E
    Satterthwait, AC
    Stura, EA
    Profy, AT
    Wilson, IA
    STRUCTURE, 1999, 7 (02) : 131 - 142
  • [23] Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope
    Zolla-Pazner, Susan
    Cohen, Sandra Sharpe
    Krachmarov, Chavdar
    Wang, Shixia
    Pinter, Abraham
    Lu, Shan
    VIROLOGY, 2008, 372 (02) : 233 - 246
  • [24] Identification of the potential regions of Epap-1 that interacts with V3 loop of HIV-1 gp120
    Bhaskar, C.
    Reddy, Palakolanu S.
    Chandra, K. Sarath
    Sabde, Sudeep
    Mitra, Debashis
    Kondapi, Anand K.
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2013, 1834 (04): : 780 - 790
  • [25] Effect of amino acid changes in the gp120 V3 loop on serological cross-reactivity of HIV-1 subtypes
    Yaroslavtseva, NG
    Shchelkanov, MY
    Yudin, AN
    Navruzbekov, GA
    Semiletov, YA
    Karamov, EV
    MOLECULAR BIOLOGY, 1997, 31 (02) : 284 - 289
  • [26] The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate
    Jagodzinski, PP
    Trzeciak, WH
    ACTA BIOCHIMICA POLONICA, 1998, 45 (03) : 799 - 804
  • [27] HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples
    Saracino, A.
    Monno, L.
    Punzi, G.
    Cibelli, D. C.
    Tartaglia, A.
    Scudeller, L.
    Brindicci, G.
    Lagioia, A.
    Scotto, G.
    Angarano, G.
    VIRUS RESEARCH, 2007, 130 (1-2) : 34 - 42
  • [28] HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism
    Roche, Michael
    Jakobsen, Martin R.
    Sterjovski, Jasminka
    Ellett, Anne
    Posta, Filippo
    Lee, Benhur
    Jubb, Becky
    Westby, Mike
    Lewin, Sharon R.
    Ramsland, Paul A.
    Churchill, Melissa J.
    Gorry, Paul R.
    JOURNAL OF VIROLOGY, 2011, 85 (09) : 4330 - 4342
  • [29] Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5
    Salimi, Hamid
    Roche, Michael
    Webb, Nicholas
    Gray, Lachlan R.
    Chikere, Kelechi
    Sterjovski, Jasminka
    Ellett, Anne
    Wesselingh, Steve L.
    Ramsland, Paul A.
    Lee, Benhur
    Churchill, Melissa J.
    Gorry, Paul R.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2013, 93 (01) : 113 - 126
  • [30] An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site
    Cohen, Carla
    Forzan, Mario
    Sproat, Brian
    Pantophlet, Ralph
    McGowan, Ian
    Burton, Dennis
    James, William
    VIROLOGY, 2008, 381 (01) : 46 - 54